A randomised phase II study of perioperative epirubicin, cisplatin and capecitabine (ECX) ± lapatinib for operable, HER-2 positive gastric, oesophagogastric junctional (OGJ) or lower oesophageal adenocarcinoma: results from the UK MRC ST03 lapatinib feasibility study (ISRCTN 46020948).
Authors
Smyth, ERowley, S
Allum, W
Stenning, S
Wotherspoon, A
Robb, C
Grabsch, H
Alderson, D
Crosby, T
Mason, R
Griffin, M
Mansoor, Was
Darby, S
Seymour, M
Thompson, J
Sothi, S
Sumpter, K
Blazeby, J
Langley, R
Cunningham, D
Issue Date
2016-10-01
Metadata
Show full item recordCitation
A randomised phase II study of perioperative epirubicin, cisplatin and capecitabine (ECX) ± lapatinib for operable, HER-2 positive gastric, oesophagogastric junctional (OGJ) or lower oesophageal adenocarcinoma: results from the UK MRC ST03 lapatinib feasibility study (ISRCTN 46020948). 2016, 27(suppl_6):LBA26 Annals of OncologyPublisher
Department of Oncology, The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, SuttonJournal
Annals of OncologyDOI
10.1093/annonc/mdw435.17Additional Links
https://academic.oup.com/annonc/article/2800526/AType
Meetings and ProceedingsLanguage
enISSN
0923-75341569-8041
ae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdw435.17